Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price for American Depositary Shares (ADSs) acquired through dividend reinvestment, which was $39.61 per ADS.
Material Changes
The filing details changes in the shareholdings of specific individuals following the reinvestment of dividends paid on October 1, 2015. There are no reported material changes to the company's financial position or operations in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider share acquisitions.
Important Facts for Investors
- Transaction Type: Directors and PDMRs acquired ADSs via dividend reinvestment.
- Transaction Price: $39.61 per ADS.
- Key Participants:
- Dr M M Slaoui: 1,918.567 ADSs
- Mr D E Troy: 1,099.657 ADSs
- Mr N Hirons: 240.867 ADSs
- Dr K Slaoui (Connected Person): 84.553 ADSs
- Notification Date: GSK was informed of these allocations on October 16, 2015.